FindTrial
Sign In

Investigation of vital prognosis of Gliadel(GLI02T)

Post-marketing surveillance of long-term observation of Gliadel wafer- Investigation of vital prognosis in patients with High grade glioma

Status
Unknown
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-jRCT1080222548
Enrollment
250
Registered
2014-06-30
Start date
2014-06-30
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malignant glioma

Interventions

investigational material(s) Generic name etc : Gliadel 7.7mg Implant INN of investigational material : carmustine Therapeutic category code : 421 Alkylating agents Dosage and Administration for Invest

Sponsors

Eisai Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: malignant glioma, patients enrolled in study GLI01S

Exclusion criteria

Exclusion criteria: 1)to contraindication of Gliadel 2)Not applicable to indications of Gliadel

Design outcomes

Primary

MeasureTime frame
Survival rate of 3 year after implantation To comfirm Survival of 3 year after implantation—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026